MTW NHS Trust West Kent CCG

Drug Status Key

  • Preferred
  • Second Line
  • Third Line
  • Specialist Initiation
  • Hospital Only
  • Not Approved for Formulary

Antibody responsive malignanacy

Drug safety update

 December 2014: Rituximab: progressive multifocal leukoencephalopathy in a patient

 December 2014: Rituximab: screen for hepatitis B virus before treatment

Nice guidance (also see drug specific guidance below)

 NG52: Non-Hodgkin’s lymphoma: diagnosis and management, July 2016
Rituximab causes the lysis of B lymphocytes and may be used to treat rheumatoid arthritis when therapy with other DMARDs including one anti-TNF has been inadequate or not tolerated.
 Systemic Anti-Cancer Therapy (SACT) guidance including pathways for managing complications and adverse events directly linked to SACT which may present both in emergency departments and on the general wards. This covers both chemotherapy and immune related toxicities.